Spoiled for choice regarding biologics in psoriasis
Biologics have revolutionised the management of moderate-to-severe psoriasis and allow clear or almost-clear skin in many patients. All biologics yield superior PASI 75 responses (ranging from 40% to >90%) when compared with methotrexate, cyclosporine, and acitretin, with better overall tolerability.
“From the IL-17 inhibitors, we have data over a treatment period of more than five years: they show that the efficacy stays the same over this period of time,” said Dr Jashin Joaquin Wu of Kaiser Permanente Los Angeles Medical Center, in his update on biologics in psoriasis .
He referred to the SCULPTURE five-year data that were published recently . A poster presented during the meeting established the high efficacy of secukinumab in difficult-to-treat regions: palmoplantar psoriasis, nail psoriasis and scalp psoriasis . This showed the results from three prospective Phase 3 studi...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab Next Article
Dual JAK/SYK inhibitor and anti-IL-33 blockade »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.